Bayesian interim analysis of phase II cancer clinical trials.
about
Design of Phase II cancer trials evaluating survival probabilitiesPhase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.Bayesian design of single-arm phase II clinical trials with continuous monitoring.Monitoring the rates of composite events with censored data in phase II clinical trials.Bayesian variable selection in cost-effectiveness analysis.Stopping rules for phase II studiesThe utility of Bayesian predictive probabilities for interim monitoring of clinical trials.Bayesian optimal design for phase II screening trialsA Bayesian approach for unplanned sample sizes in phase II cancer clinical trialsBayesian methods for design and analysis of cost-effectiveness trials in the evaluation of health care technologies.Bayesian sequential monitoring design for two-arm randomized clinical trials with noncompliance.A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation.Phase II clinical trials in oncology: strengths and limitations of two-stage designs.A Bayesian re-assessment of two Phase II trials of gemcitabine in metastatic nasopharyngeal cancerFailsafe automation of Phase II clinical trial interim monitoring for stopping rules.Statistical designs for early phases of cancer clinical trials.Choice of futility boundaries for group sequential designs with two endpoints.Decision theoretic designs for phase II clinical trials with multiple outcomes.MIDAS: a practical Bayesian design for platform trials with molecularly targeted agents.A predictive probability design for phase II cancer clinical trials.Prospective application of Bayesian monitoring and analysis in an "open" randomized clinical trial.The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies.Bayesian two-stage designs for phase II clinical trials.Accounting for patient heterogeneity in phase II clinical trials.BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints.Bayesian designs with frequentist and Bayesian error rate considerations.
P2860
Q24802587-5CB9858A-99BF-4C47-B1E5-23DD3F5E6D39Q27851528-7A84195B-0F93-4E3A-8AA6-4B131E571013Q30484175-AAC44EE3-554D-45F1-9803-1F1ECFACCF1BQ30679019-BF046F93-53F5-4353-891D-DCA6C34743FFQ33859002-D3D83912-6DDB-4C6B-A1CD-1712C8E0FC1FQ34291279-B72C376B-5681-4AFC-9E70-9D3F7564B1AAQ34421870-45FCDF64-3AAA-4C02-9A0C-9C148B90B568Q34788534-83615038-10E7-4C9F-B93F-06F74AEEB84AQ34815765-463FF84C-1638-4107-89F0-52389241B2CCQ35040675-40B07B7E-41EC-4961-85C8-D2A38B369A8CQ35572069-CCFF05C5-5891-42B7-92BF-1B5C732F14E5Q35619916-85D16FB8-4570-4C34-A482-C356C6DA6200Q36508078-577E7C2E-A819-46B7-BB2A-9F2D0B307FB8Q36623751-947AC1C2-B389-46C2-923F-125407F9C5A6Q37692738-253EE814-EE9B-443A-BC35-A7A7DC8D547FQ38052915-EAF2DB2E-2619-4D14-8B24-B5560A5FCBB1Q40090419-F41513C0-5A4B-4272-9FC5-5F4950CE2023Q40712207-F42B44E4-2C96-4CD3-B3A1-40F9F82BEFE1Q41662421-1E74115D-B8ED-4859-B618-C22509629BE7Q42109216-6C5C2168-9B3A-4EF8-9A33-EC57B9F75D3AQ42667274-C6FAB5E9-BA6C-4252-9CBC-44E2A9729587Q43745833-0A393F94-1C42-4487-9224-4B3C05CB534FQ44059928-EE0B402A-41CD-4E83-89E4-C08FB1E23F3BQ47157890-E0D43480-CD18-4E6D-8C3D-FF864363E712Q48316015-2F639474-8618-4801-B6BB-2193F00EC8E4Q51961283-622BBA12-52D4-48F9-B252-E21611EF8B1E
P2860
Bayesian interim analysis of phase II cancer clinical trials.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Bayesian interim analysis of phase II cancer clinical trials.
@en
Bayesian interim analysis of phase II cancer clinical trials.
@nl
type
label
Bayesian interim analysis of phase II cancer clinical trials.
@en
Bayesian interim analysis of phase II cancer clinical trials.
@nl
prefLabel
Bayesian interim analysis of phase II cancer clinical trials.
@en
Bayesian interim analysis of phase II cancer clinical trials.
@nl
P1476
Bayesian interim analysis of phase II cancer clinical trials.
@en
P2093
Heitjan DF
P304
P356
10.1002/(SICI)1097-0258(19970830)16:16<1791::AID-SIM609>3.0.CO;2-E
P407
P577
1997-08-01T00:00:00Z